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Abstract 
OBJECTIVE:  To investigate the potential difference in vaccine effectiveness among Active 
Duty Air Force (ADAF) personnel vaccinated against influenza from 2007-2011.  Particularly, to 
determine if any difference in the protection offered is based on sex, vaccine type, or both. 
 
METHODS:  The proposed study incorporated a cross-sectional design using the Department of 
Defense’s (DoD) comprehensive databases.  Laboratory-confirmed influenza and other 
Influenza-Like Illness (ILI) cases were identified for each of the four influenza seasons of 
interest, vaccination status and history was then verified, and 2x2 tables were constructed in 
order to calculate odds ratios. 
 
RESULTS:  No consistent difference in vaccine effectiveness in regards to sex of the subject 
could be demonstrated.  For the ’10-’11 season, males were 42% less likely to develop influenza 
than females (OR 0.5820, 95% CI 0.3400-1.009).  However, this finding was directly 
contradicted by the two analyses conducted for the ’08-’09 season which demonstrated that 
males had an increased risk of influenza infection (OR 1.483, 95% CI 1.214-1.813 & OR 1.422, 
95% CI 1.010-2.027 respectively).  For the ‘07-‘08, ‘08-‘09, and ‘10-’11 seasons, subjects who 
received the injectable trivalent (TIV) form of the vaccine achieved significantly better 
protection against acquiring influenza than did those who received the nasal (LAIV) form 
(0.5088, 95% CI 0.3094 – 0.8264; OR 0.7266, 95% CI 0.6095-0.8663; OR 0.6724, 95% CI 
0.4945-0.9111; & OR 0.5297, 95% CI 0.3189-0.8683 respectively).  This did not hold true for 
either analysis conducted for the ’09-’10 season. 
 
CONCLUSIONS:  No demonstrable differences in influenza vaccine effectiveness were found 
among ADAF personnel vaccinated between 2007 through 2011 based on sex.  However, during 
that same period of time, those who received the TIV form were better protected than those who 
received the LAIV.  
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Differences in Immunity Offered by the Influenza Vaccination among  
Active Duty US Air Force Personnel from 2007-2011 
The CDC estimates that anywhere from 5% to 20% of the U.S. population is affected by 
influenza each year, resulting in more than 200,000 hospitalizations (Centers for Disease Control 
and Prevention, 2011).  In 2007, it ranked as the 8
th
 leading cause of death in the U.S. with an 
estimated total of 52,717 (Centers for Disease Control and Prevention, 2010).  While the U.S. 
Military population as a whole is typically younger and healthier than the average, a variety of 
factors place them at increased risk for respiratory epidemics such as influenza.  Factors such as 
crowded living conditions, stressful working environment, and exposure to respiratory pathogens 
in disease-endemic areas, all contribute to this higher risk (Gray, Callahan, Hawksworth, Fisher, 
& Gaydos, 1999).   
It has been estimated that as much as 25 to 30 percent of all outpatient illnesses, as well 
as hospitalizations, among U.S. military personnel result from respiratory infections (Gray, 
1995).  Obviously the widespread devastation which occurred among U.S. military forces during 
the great 1917 influenza pandemic are often cited as ominous examples, but one needn’t go back 
that far to see influenza’s detrimental effects on military operations.  In 1996, the crew of the 
U.S.S. Arkansas fell victim to an influenza that did not match the strains in the vaccine they had 
received.  Forty two percent of the ship’s company fell ill, and the rate of incapacitation forced 
the ship to make an unscheduled return to port (Earhart et al., 2001). 
In order to help combat this high rate of infection, the U.S. Department of Defense (DoD) 
instituted mandatory vaccination programs for all service members (both active duty and reserve) 
and have required annual influenza vaccinations since the 1950’s (Grabenstein, Pittman, 
Greenwood, & Engler, 2006).  Thus the Air Force (AF), like its sister services, mandates annual 
DIFFERENCES IN INFLUENZA VACCINATION IMMUNITY 6 
 
influenza vaccination for all personnel, with the exception of those who have known 
contraindications.  A complete list of contraindications is available through the CDC at 
http://www.cdc.gov/vaccines/recs/vac-admin/downloads/contraindications-guide-508.pdf 
(Centers for Disease Control & Prevention, 2006). 
Over this six decade period, the predominate form of vaccination has been the injectable 
Trivalent Inactivated vaccines (TIV).  However, since the 2003-2004 season, the Air Force has 
preferentially given the Live Attenuated Influenza Vaccine (LAIV, available commercially as 
FluMist®) nasal spray to personnel.  The exception to this rule was the supplemental pandemic 
vaccine given during the ’09-’10 season.  This vaccine was overwhelmingly given as an 
injectable form (91.4% to 8.6% based on the analysis conducted for this study). 
In addition to compulsory vaccinations, the U.S. Military also maintains extensive 
databases containing demographic, occupational, immunization, and medical encounter data for 
its members.  Three of these databases were used to gather data for this study. 
The first is the DoD Global Laboratory-based Influenza Surveillance System Program.  
This database is available through the U.S. Air Force’s School of Aerospace Medicine 
(USAFSAM), located at Wright-Patterson AFB, OH.  It documents Influenza-like Illness (ILI) 
clinic visits, including lab-confirmed influenza cases, within the DoD.  In addition to laboratory 
results including specific identification of the influenza strain, about half of the personnel 
reflected in the data also have questionnaire responses which include date/type of vaccinations 
and personal vaccination histories. 
Another important database to this study will be the Air Force Complete Immunization 
Tracking Application (AFCITA).  As the name implies, this database contains records of all 
immunizations (including influenza in its various forms) given to AF personnel.  Finally, the 
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Composite Health Care System (CHCS) is used by all U.S. Military Health Care centers to track 
medical information.  This includes, but is not limited to providers’ notes, lab results, and 
diagnoses. 
The presence then of the mandatory vaccinations, AFCITA, CHCS, the Influenza 
Surveillance Program, and an essentially socialized medical treatment system makes the USAF a 
particularly rife source of data from which to study influenza.  This fact was acknowledged by 
the FDA’s Vaccines and Related Biological Products Advisory Committee (VRBPAC) when it 
asked the DoD what is known about military personnel who are vaccinated but still become a 
case of influenza (Vaccines and Related Biological Products Advisory Committee, 2009). 
Research Questions 
The primary research question was to determine whether or not, among Active Duty Air 
Force (ADAF) personnel who were vaccinated against influenza from 2006-2011, males are 
provided better protection from influenza vaccines than females.  Unfortunately, due to problems 
with data from the ‘06-’07 influenza season, the time was shortened to 2007-2011.  Lack of 
vaccine protection was determined by lab-confirmed influenza.  Therefore, protection was 
defined as lack of lab-confirmed influenza in those who had a clinic visit for an ILI.   
In addition to sex, this data also provides an opportunity to look at differences in 
immunity provided by virtue of vaccine type alone over several seasons.  This was accomplished 
by using the same criteria for establishing cases vs. controls, and then simply comparing them 
based on the type of vaccine each received, TIV vs. LAIV. 
If no difference exists with regards to either of these questions, this would then mean that 
some other factor affected the vaccine’s effectiveness in a given individual.  There are many 
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possibilities including age, location, length of time between vaccination and clinic visit, and 
strain of influenza; among others. 
Review of Literature 
In 2009, Eick, Wang, Hughes, Ford, and Tobler compared the effectiveness of TIV vs. 
LAIV among U.S. military service members, primarily U.S. Army and Air Force during two 
consecutive flu seasons, 2005-2006, and 2006-2007.  Their comparisons were in populations of 
recruits, those new to military service, vs. similar exposure groups of non-recruits.  They 
concluded that among non-recruits TIV provided a slightly greater protection from influenza-like 
illness compared to LAIV.  However, in recruit populations, LAIV was found to provide 
significantly greater protection from influenza-like illnesses compared to TIV.  They surmised 
that possible reasons for these differences include differences in pre-existing influenza antibody 
levels, differing respiratory disease burden, and/or unmeasured confounding (Eick, Wang, 
Hughes, Ford, & Tobler, 2009). 
It should be noted that while they did use Defense Medical Surveillance System (DMSS) 
for this study, they did not restrict positive results to laboratory-confirmed influenza cases.  As a 
result, they used 14 different ICD-9 codes which they considered representative of influenza-like 
illnesses (ILI’s).  This limited a more specific study of the vaccines’ effectiveness. 
This specificity may be of more concern given the reemergence of H1N1, and the results 
found by Rosella, Groenwold, and Crowcroft (2011).  In their soon-to-be-published article 
examining effectiveness of vaccination against the H1N1 virus, they found that even after 
adjusting for confounding factors those who received vaccine during the 2009 flu season were at 
greater risk for acquiring an H1N1 infection than those who were not vaccinated (Rosella, 
Groenwold, & Crowcroft, 2011).  This potentially has a greater impact on ADAF personnel, as 
DIFFERENCES IN INFLUENZA VACCINATION IMMUNITY 9 
 
their age range puts them at increased risk for morbidity and mortality associated with the H1N1 
virus. 
In a study published in 2010, Johns et al. found that previous seasonal vaccination via 
either TIV or LAIV provided improved immunologic protection (Johns et al., 2010).  This could 
further help to explain increased vaccine effectiveness among non-recruits vs. those who were 
immunologically-naïve.  They also recommended further study of such populations, as well as 
attempts to better define the potential biologic diversities related to age, sex and background 
disease states. 
In a recently published study of vaccine effectiveness among military recruits in 
Singapore, vaccination against H1N1 during the 2009 pandemic was found to reduce relative risk 
by 86%.  Of 249 cases of H1N1 reported between 11 May 2009 and 25 June 2010, 43 were 
considered vaccine failures (Lee et al., 2011). 
One other recent development is the question of method of administration of the TIV.  On 
26 October 2011, the FDA raised concerns over the use of Jet Injectors vs. sterile needle and 
syringes.  Specifically, the agency is yet convinced of the safety and efficacy of this method of 
administration, and therefore has not approved it (FDA, 2011).  This method is still employed by 
the USAF in the vaccination of new recruits. 
Methodology 
Laboratory-confirmed influenza and other ILI cases were identified using the DoD 
Global Laboratory-based Influenza Surveillance Program.  These represented Active Duty Air 
Force personnel who presented to one of the surveillance sites with a clinical syndrome 
indicative of influenza, and who subsequently underwent confirmatory testing using either 
reverse transcriptase polymerase chain reaction (RT-PCR) or viral culture methods.  Positives 
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(cases) were defined as those who had a positive influenza result; whereas negatives (controls) 
were those who had a result of either no virus isolated, or a virus other than influenza. 
Vaccination status and history was then verified using AFCITA.  Any subject who was 
vaccinated after being tested, or whose vaccination date could not be verified, was eliminated 
from the study.  Additionally, to eliminate potential false positives, individuals who received 
their influenza vaccination within 14 days prior to being tested were also eliminated. 
Data was initially sought for five influenza seasons, 2006-‘07, ’07-’08, ’08-’09, ’09-’10, 
and ’10-’11.  Unfortunately data gaps were too excessive for the ’06-’07 season, and it was 
therefore eliminated from consideration.  However, this still allowed study of one season prior 
(’07-’08) to the appearance of Pandemic H1N1 (pH1N1), the emergence of the pandemic 
without a supplemental vaccine (’08-’09), the year of the supplemental vaccine (’09-’10), and 
the first year in which the pandemic influenza was included in the routine vaccination (’10-’11). 
Cases and controls for each respective influenza season were then compared with regards 
to sex.  As AFCITA also reports type of vaccine (LAIV vs. TIV) issued, a comparison of 
effectiveness with regards to vaccine type vs. sex, as well as vaccine type alone were also 
studied.  In order to eliminate pregnancy as a potential confounder, pregnant females were 
excluded. 
For the ’08-’09 and ’09-‘10 seasons, cases of pH1N1 were separated out, resulting in two 
analyses for each of those years.  As only one vaccine composition was offered for ’08-’09, one 
analysis was performed assessing all positive influenzas (including pH1N1) as cases, with a 
separate analysis performed after excluding all those positive for pH1N1.  This exclusion was 
due to pH1N1’s likely confounding affect when included with all influenzas from that season.  
Cases which were positive for pH1N1 were not treated as negatives for purposes of this second 
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analysis.  For ’09-’10, the presence of a supplemental vaccine allowed two completely separate 
analyses, almost as if it were two different influenza seasons.  There was however, much overlap 
of the controls.  The first analysis looked at only those which were positive for seasonal 
influenzas as cases.  Both cases and controls had to have received their seasonal influenza 
vaccine (regardless of form) prior to being tested, and those positive for pH1N1 were not 
counted as controls.  Likewise for the second analysis, both cases and controls had to have 
received their supplemental vaccine (again regardless of form) prior to being tested, and those 
positive for seasonal influenza were excluded as controls.   
In the ’09-’10 study population, seasonal influenzas vaccinations were given from 14 
Aug 2009 through 16 Aug 2010, while the supplemental H1N1 vaccination dates were from 15 
Oct 2009 through 8 July 2010.  So as an example, a subject who received the seasonal vaccine on 
14 Aug 2009, tested negative for influenza on 1 Oct 2009, but didn’t receive the supplemental 
vaccine until 1 Nov 2009; could be used as a control only for the seasonal influenza arm, not for 
the pH1N1 arm.  This difference in timing between vaccinations and testing accounts for the 
differences in controls between the two ’09-’10 analyses. 
Crude odds ratios (OR) were calculated for comparing cases to controls using sex, 
vaccine type, and both.  When calculating p-values for the small numbers of cases encountered 
during the ’09-’10 season, the one-sided Fisher’s exact test was used.  All statistical analysis was 
performed using Stata/SE, ver. 9.2 for Windows (Copyright 1984-2007, StataCorp, 4905 
Lakeway Drive, College Station, Texas 77845 USA). 
The study was reviewed by both the Air Force Research Laboratory (AFRL), and Wright 
State University Institutional Review Boards.  Both determined the study did not constitute 
human use research.  No external funding was used to conduct this research. 
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Figure 1. Global map showing DoD Installations which currently serve as influenza surveillance sites 
Results 
‘10-‘11: 
In the initial dataset, there were 628 records total; 145 being eliminated for missing data, 
including no confirmatory testing, no date of vaccination, no reported gender, and missing 
vaccine types.  Of the remaining 483, 399 (Table 1-1) should have acquired immunity based on 
appropriate vaccination dates.  The other 94 were eliminated either due to receiving their vaccine 
after they had been tested, within the 14 day window, or had received their vaccine in a prior flu 
season.  315 (78.9%) of those included in the study were males and 84 (21.1%) females.  156 
(39.1%) received the TIV, while 243 (60.9%) received the LAIV. 
There were a total of 111 (27.8%) subjects who had a positive result for one of the 
surveyed types of influenza; 67 (60.4%) of these were positive for a seasonal influenza, with the 
remaining 44 (39.6%) testing positive for pH1N1.  Males constituted 80 (72.1%) of those who 
tested positive.  Of whom 56 (70%), received the LAIV, compared with 24 (30%) who received 
the TIV.  Females made up 31 (27.9%) of the positives; 22 (71.0%) of these received the LAIV, 
DIFFERENCES IN INFLUENZA VACCINATION IMMUNITY 13 
 
compared to 9 (29.0%) who received the TIV.  The remaining 288 (72.2%) had a result of either 
no virus isolated, or a virus other than influenza.  Of those, 136 (57.9%) received the LAIV.  The 
other 99 (42.1%) received the TIV.    




Vaccine Type # of 
obs 
Percent Mean Age s Min Age Max Age 
-------- ----------- ----------- 399 100.0 28.43 7.0522 18 53 
 Positive  ----------- 111 27.8 30.41 7.0882 19 53 
 Negative  ----------- 288 72.2 27.67 6.9004 18 50 
         
 ----------- LAIV 243 60.9 29.20 6.3787 18 50 
 ----------- TIV 156 39.1 27.23 7.8616 18 53 
         
Male ----------- ----------- 315 78.9 (100.0) 28.32 7.0019 18 50 
 Positive ----------- 80 20.1 (25.4) 30.66 6.5525 20 50 
  LAIV 56 14.0 (17.8) 31.27 6.0045 21 46 
  TIV 24 6.0 (7.6) 29.25 7.6343 20 50 
         
 Negative ----------- 235 58.9 (74.6) 27.52 6.9837 18 50 
  LAIV 136 34.1 (43.2) 28.29 6.1883 18 50 
  TIV 99 24.8 (31.4) 26.46 7.8588 18 46 
         
Female ----------- ----------- 84 21.1 (100.0) 28.85 7.2652 18 53 
 Positive ----------- 31 7.8 (36.9) 29.74 8.3983 19 53 
  LAIV 22 5.5 (26.2) 30.18 7.9919 19 46 
  TIV 9 2.3 (10.7) 28.67 9.7468 20 53 
 Negative ------------ 53 13.3 (63.1) 28.32 6.5421 18 46 
  LAIV 29 7.3 (34.5) 28.72 5.8913 19 46 
  TIV 24 6.0 (28.6) 27.83 7.3524 18 44 
 
For the study population during this season, males were 42% less likely to develop 
influenza (Table 1-2) than females (OR 0.5820, 95% CI 0.3400-1.009).  However, this 
confidence Interval is quite broad and should be considered clinically indifferent. 
Table 1-2. Sex vs. Influenza analysis for ’10-‘11 
 
 +Influenza - Influenza Total 
Males 80 235 315 
Females 31 53 84 
Total 111 288 399 
Odds Ratio 0.5820  
95% CI 0.3400-1.009  
p-value 0.0365  
Chi-Square Statistic 4.37  
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However, when all subjects were compared, those who received the TIV were 49% less 
likely (Table 1-3) to have a positive influenza than those who received the LAIV form of the 
vaccine (OR 0.5088, 95% CI 0.3094 – 0.8264).   




+Influenza - Influenza Total 
TIV 33 123 156 
LAIV 87 165 252 
Total 120 288 408 
Odds Ratio 0.5088  
95% CI 0.3094 – 0.8264  
p-value 0.0040  
Chi-Square Statistic 8.30  
 
Additionally, when looking at males only (Table 1-4) there was a tendency towards better 
protection from TIV (OR 0.5887).  But, this unfortunately narrowly missed reaching statistical 
significance (p-value 0.0548). 
Table 1-4. Vaccine form vs. Influenza analysis, Males only for ’10-‘11 
 
Males Only +Influenza - Influenza Total 
TIV 24 99 123 
LAIV 56 136 192 
Total 80 235 315 
Odds Ratio 0.5887  
95% CI 0.3261-1.043  
p-value 0.0548  
Chi-Square Statistic 3.69  
 
Gender and age group comparisons between ADAF personnel at the early part of the 
influenza season and the study group (Table 1-5) demonstrated a reasonable degree of similarity. 
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Table 1-5. Comparison of USAF Active Duty personnel to the ‘10-‘11 study population 
 
USAF End Strength - September 2010 Study Group 
 
# % # % 







18.5 17-24 FEMALE 
MALE 85,899 80.4 123 81.5 
TOTAL 106,808 100 151 100 








MALE 114,985 80.3 130 76.5 
TOTAL 143,235 100 170 100 








MALE 57,334 83.3 54 80.6 
TOTAL 68,792 100 67 100 








MALE 9793 83.0 8 72.7 







MALE 268,011 81.1 315 79.0 
TOTAL 330,629 100 399 100 
 
Table 1-6 demonstrates the array of viruses, as well as frequency and percentages which 
were captured during the ’10-’11 influenza season.  
Table 1-6. Viruses identified for the 10-11 study population by laboratory testing 
 
Virus Isolated Freq. Percent 
No Virus Isolated 259 64.91 
Adenovirus 16 4.01 
Enterovirus 2 0.50 
Parainfluenza 5 1.25 
RSV 6 1.50 
Influenza A/H3 33 8.27 
Influenza B 20 5.01 
Sequence A/H3 13 3.26 
Sequence Influenza B 1 0.25 
Pandemic Influenza A/H1N1 28 7.02 
Sequence A/pH1N1 16 4.01 
   
Total 399 100.00 
 
Tables 1-7 through 1-9 represent the remaining analysis which failed to reach a degree of 
statistical significance. 
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Table 1-7. Vaccine form vs. Influenza analysis, Females only for ’10-‘11 
 
Females Only +Influenza - Influenza Total 
TIV 9 24 33 
LAIV 22 29 51 
Total 31 53 84 
Odds Ratio 0.4943  
95% CI 0.1685-1.387  
p-value 0.1411  
Chi-Square Statistic 2.17  
 
Table 1-8. Sex vs. Influenza analysis for LAIV only, ’10-‘11 
 
LAIV Only +Influenza - Influenza Total 
Males 56 136 190 
Females 22 29 51 
Total 78 165 241 
Odds Ratio 0.5427  
95% CI 0.2749-1.085  
p-value 0.0575  
Chi-Square Statistic 3.61  
 
Table 1-9. Sex vs. Influenza analysis for TIV only, ’10-‘11 
 
TIV Only +Influenza - Influenza Total 
Males 24 99 123 
Females 9 24 33 
Total 33 123 156 
Odds Ratio 0.6464  
95% CI 0.2495-1.794  
p-value 0.3324  
Chi-Square Statistic 0.94  
 
 ‘09-‘10: 
In the initial dataset, there were 1,355 records total; 627 were eliminated for the same 
reasons as those eliminated from the ’10-’11 portion (i.e. no confirmatory testing, no date of 
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vaccination, etc.).  As with the previous season, age group and gender comparisons showed 
reasonable similarity (Table 2-1). 
Table 2-1.  Comparison of USAF Active Duty personnel to the ‘09-‘10 seasonal influenza study 
population 
 
USAF End Strength - September 2009 Study Group 
 
# % # % 







29.8 17-24 FEMALE 
MALE 85,714 78.8 198 70.2 
TOTAL 108,748 100 282 100 








MALE 106,586 79.4 222 75.0 
TOTAL 134,198 100 296 100 








MALE 60,762 84.4 106 79.7 
TOTAL 71,990 100 133 100 








MALE 11,436 84.1 14 82.4 







MALE 264,498 80.5 540 74.2 
TOTAL 328,532 100 728 100 
 
Of the remaining 728, 554 (Table 2-2) were selected to analyze for seasonal influenza 
only.  Of those chosen for the seasonal only analysis, 404 (72.9%) were males and 150 (27.1%) 
females; 216 (39.0%) received the TIV, while 383 (61.0%) received the LAIV.  There were a 
total of 11 (2.0%) subjects who had a positive result for one of the surveyed types of influenza.  
Males were 9 (81.8%) of those who tested positive.  Of whom 6 (67%), received the LAIV, 
compared with 3 (33%) who received the TIV.  Females constituted 2 (18.2%) of the positives, 
with one each receiving the LAIV and TIV.  The remaining 543 (98.0%) had a result of either no 
virus isolated, or a virus other than influenza.  Of those, 331 (59.7%) received the LAIV.  The 
other 212 (40.3%) received the TIV.   
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‘09-‘10 Seasonal Influenza Only 
Table 2-2. Snapshot of ’09- ’10 Seasonal Influenza only study population   *Negatives do not 






# of obs Percent Mean Age s Min Age Max Age 
-------- ----------- ----------- 554 100.0 28.32 7.3871 18 55 
 Positive  ----------- 11 2.0 27.64 6.2173 21 39 
 Negative  ----------- 543 98.0 28.33 7.4130 18 55 
         
 ----------- LAIV 338 61.0 28.24 6.9274 18 49 
 ----------- TIV 216 39.0 28.44 8.0692 18 55 
         
Male ----------- ----------- 404 72.9 (100.0) 28.82 7.5760 18 55 
 Positive ----------- 9 1.6 (2.2) 28.11 6.8089 21 39 
  LAIV 6 1.1 (1.5) 27.17 6.6458 21 39 
  TIV 3 0.5 (0.7) 30.00 8.1853 23 39 
         
 Negative ----------- 395 71.3 (97.8) 28.83 7.5996 18 55 
  LAIV 250 45.1 (61.9) 28.80 7.1030 19 49 
  TIV 145 26.2 (35.9) 28.90 8.4127 18 55 
         
Female ----------- ----------- 150 27.1 (100.0) 26.98 6.6942 18 51 
 Positive ----------- 2 0.4 (1.3) 25.50 2.1213 24 27 
  LAIV 1 0.2 (0.7) 24.00 ----------- 24 24 
  TIV 1 0.2 (0.7) 27.00 ----------- 27 27 
 Negative ------------ 148 26.7 (98.7) 27.00 6.7350 18 51 
  LAIV 81 14.6 (54.0) 26.67 6.2109 18 45 
  TIV 67 12.1 (44.7) 27.40 7.3465 18 51 
 
Table 2-3 demonstrates the array of viruses, as well as frequency and percentages which 
were present in the seasonal only population for the ’09-’10 season.   
Table 2-3. Viruses identified for the 09-10 seasonal influenza study population by laboratory 
testing 
 
Virus Isolated Freq. Percent 
No Virus Isolated 513 92.60 
Adenovirus 12 2.17 
Enterovirus 1 0.18 
Parainfluenza 15 2.71 
RSV 2 0.36 
Influenza A 6 1.08 
Influenza A/H3 1 0.18 
Influenza B 1 0.18 
Sequence A/H3 1 0.18 
Sequence B/Victoria 2 0.36 
   
Total 554 100.00 
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Of the 174 chosen for the pH1N1 analysis (Table 2-4); 136 (78.2%) were males and 38 
(21.8%) females.  TIV was given to 159 (91.4%), while 15 (8.6%) received the LAIV.  There 
were a total of 6 (3.4%) subjects who had a positive result for pH1N1 influenza, and 5 (83.3%) 
of those who were male.  Only 1 (20%) of these received the LAIV, with the other 4 (80%) 
receiving the TIV.  Only 1 (16.7%) of the positives were female, and she had received the TIV.  
The remaining 168 (96.6%) had a result of either no virus isolated, or a virus other than 
influenza.  Of those, 14 (8.3%) received the LAIV.  The other 154 (91.7%) received the TIV.    
Due to only 1 female being positive for pH1N1 influenza during this season, and also given that 
she received the TIV as her vaccination form; analyses of females only, LAIV only, or vaccine 
forms were unable to be conducted for this data set.  Furthermore, an additional 101 subjects 
who tested negative for influenza had received a preservative-free form of the TIV.  As there 
were no positive cases which had received this form of the vaccine, these 101 were also removed 
from analysis. 
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‘09-‘10 pH1N1 Influenzas Only 
 





# of obs Percent Mean Age s Min Age Max Age 
-------- ----------- ----------- 174 100.0 27.65 7.3349 18 51 
 Positive  ----------- 6 3.4 24.33 3.8297 21 30 
 Negative  ----------- 168 96.6 27.77 7.4085 18 51 
         
 ----------- LAIV^ 15 8.6 29.07 6.7344 21 44 
 ----------- Injection# 159 91.4 27.56 7.3947 18 51 
         
Male ----------- ----------- 136 78.2 (100.0) 27.78 7.6048 18 51 
 Positive ----------- 5 2.9 (3.7) 23.20 2.9496 21 28 
  LAIV^ 1 0.6 (0.7) 22.00 ----------- 22 22 
  Injection# 4 2.3 (2.9) 23.50 3.3166 21 28 
         
 Negative ----------- 131 75.3 (96.3) 27.95 7.6780 18 51 
  LAIV^ 7 4.0 (5.1) 31.86 7.1047 25 44 
  Injection# 124 71.3 (91.2) 27.74 7.6765 18 51 
         
Female ----------- ----------- 38 21.8 (100.0) 27.18 6.3453 18 41 
 Positive ----------- 1 0.6 (2.6) 30.00 ----------- 30 30 
  LAIV^ 0 ----------- ----------- ----------- ----------- ---------- 
  Injection# 1 0.6 (2.6) 30.00 ----------- 30 30 
 Negative ------------ 37 21.3 (97.4) 27.11 6.4152 18 41 
  LAIV^ 7 4.0 (18.4) 27.29 5.8513 21 38 
  Injection# 30 17.2 (78.9) 27.07 6.6329 18 41 
*Negatives do not include Seasonal Influenza positives 
#There were 101 negatives who received the preservative-free form of the Pandemic Influenza Injection, none of which resulted in a positive 
Pandemic case.  Therefore, these 101 have not been included in this analysis. 
^No 2x2 tables were generated for Females only, Vaccine Forms, or LAIV only. 
 
Table 2-5 demonstrates the array of viruses, as well as frequency and percentages which 
were present in the seasonal only population for the ’09-’10 season.   
Table 2-5. Viruses identified for the ‘09-‘10 pandemic study population by laboratory testing 
 
Virus Isolated Freq. Percent 
No Virus Isolated 155 89.08 
Adenovirus 6 3.45 
Parainfluenza 7 4.02 
Sequence A/pH1N1 6 3.45 
   
Total 174 100.00 
 
None of the analyses for ’09-’10 produced any statistically significant results.  All 
Confidence Intervals crossed 1, and p-values were far above the acceptable threshold of 0.05.  
These are all demonstrated in Tables 2-6 through 2-14. 
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Table 2-6. Sex vs. Influenza analysis, Seasonal Influenza only for ’09-’10 
 +Influenza - Influenza Total 
Males 9 395 404 
Females 2 148 150 
Total 11 543 554 
Odds Ratio 1.686  
95% CI 0.3430-16.19  
Fisher’s Exact p (1-sided) 0.3910  
 
Table 2-7. Vaccine form vs. Influenza analysis, Seasonal Influenza only for ’09-’10 
Vaccine Forms 
 
+Influenza - Influenza Total 
TIV 4 212 216 
LAIV 7 331 338 
Total 11 543 554 
Odds Ratio 0.8921  
95% CI 0.1892-3.559  
Fisher’s Exact p (1-sided) 0.5609  
 
Table 2-8. Vaccine form vs. Influenza analysis, Males only, Seasonal Influenza only for ’09-’10 
Males Only +Influenza - Influenza Total 
TIV 3 145 148 
LAIV 6 250 256 
Total 9 395 404 
Odds Ratio 0. 8620  
95% CI 0.1375-4.110  
Fisher’s Exact p (1-sided) 0.5679  
 
Table 2-9. Vaccine form vs. Influenza analysis, Females only, Seasonal Influenza only for ’09-
’10 
Females Only +Influenza - Influenza Total 
TIV 1 67 68 
LAIV 1 81 82 
Total 2 148 150 
Odds Ratio 1.208  
95% CI 0.0151-96.05  
Fisher’s Exact p (1-sided) 0.7028  
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Table 2-10. Sex vs. Influenza analysis for LAIV, Seasonal Influenza only, ’09-’10 
LAIV Only +Influenza - Influenza Total 
Males 6 250 256 
Females 1 81 82 
Total 7 331 338 
Odds Ratio 1.944  
95% CI 0.2302-90.49  
Fisher’s Exact p (1-sided) 0.4618  
 
Table 2-11. Sex vs. Influenza analysis for TIV, Seasonal Influenza only, ’09-’10 
TIV Only +Influenza - Influenza Total 
Males 3 145 148 
Females 1 67 68 
Total 4 212 216 
Odds Ratio 1.386  
95% CI 0.1088-73.83  
Fisher’s Exact p (1-sided) 0.6257  
 
Table 2-12. Sex vs. Influenza analysis, pH1N1 only for ’09-’10 
  +Influenza - Influenza Total 
Males 5 131 136 
Females 1 37 38 
Total 6 168 174 
Odds Ratio 1. 412  
95% CI 0.1508-68.56  
Fisher’s Exact p (1-sided) 0.6096  
 
Table 2-13. Vaccine form vs. Influenza analysis, Males only, pH1N1 only for ’09-’10 
Males Only +Influenza - Influenza Total 
TIV 4 124 128 
LAIV 1 7 8 
Total 5 131 136 
Odds Ratio 0. 2258  
95% CI 0.0189-12.69  
Fisher’s Exact p (1-sided) 0.2650  
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Table 2-14. Sex vs. Influenza analysis for TIV, pH1N1 only, ’09-’10 
TIV Only +Influenza - Influenza Total 
Males 4 124 128 
Females 1 7 8 
Total 5 131 136 
Odds Ratio 0. 2258  
95% CI 0.0189-12.69  
Fisher’s Exact p (1-sided) 0.2650  
  
‘08-‘09: 
In the initial dataset, there were 3,660 records total; 1,336 were excluded for the same 
reasons as those eliminated from the previous seasons (i.e. no confirmatory testing, no date of 
vaccination, etc.).  Also as with previous seasons, age group and gender comparisons showed 
reasonable similarity (Table 3-1).   
Table 3-1. Comparison of USAF Active Duty personnel to the ‘08-‘09 study population 
USAF End Strength - September 2008 Study Group 
 
# % # % 







28.3 17-24 FEMALE 
MALE 82,460 78.2 692 71.7 
TOTAL 105,513 100 965 100 






      
28.6 FEMALE 
MALE 103,362 79.4 680 71.4 
TOTAL 130,247 100 952 100 








MALE 62,519 84.8 249 72.8 
TOTAL 73,731 100 342 100 








MALE 11,018 84.0 45 69.2 







MALE 259,359 80.4 1666 71.7 
TOTAL 322,604 100 2324 100 
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The remaining 2,324 (Table 3-2) were suitable for analysis, of which 1,666 (71.7%) were 
males and 658 (28.3%) females.  TIV was given to 1,060 (45.6%), while 1,264 (54.4%) received 
the LAIV.  There were a total of 824 (35.5%) subjects who had a positive result for one of the 
surveyed types of influenza; 212 (25.7%) of these were for seasonal varieties, leaving 612 
(74.3%) with a positive result for pH1N1.  Males constituted 632 (76.7%) of those who tested 
positive.  With 391 (61.9%), receiving the LAIV, compared with 241 (38.1%) who received the 
TIV.  Females represented the other 192 (23.3%) positives; with 99 (51.6%) receiving the LAIV 
and 93 (48.4%) TIV.  The remaining 1,500 (64.5%) had a result of either no virus isolated, or a 
virus other than influenza.  Of those, 1,264 (84.3%) received the LAIV.  The other 236 (17.7%) 
received the TIV.   
‘08-‘09 All Subjects 
 









s Min Age Max Age 
-------- ----------- ----------- 2324 100.0 27.58 7.2220 17 60 
 Positive  ----------- 824 35.5 27.16 6.5116 18 54 
 Negative  ----------- 1500 64.5 27.81 7.5761 17 60 
         
 ----------- LAIV 1,264 54.4 28.41 6.6905 18 50 
 ----------- TIV 1,060 45.6 26.59 7.6956 17 60 
         
Male ----------- ----------- 1666 71.7 (100.0) 27.66 7.2352 17 60 
 Positive ----------- 632 27.2 (37.9) 27.44 6.5542 18 50 
  LAIV 391 16.8 (23.5) 28.04 6.3035 18 50 
  TIV 241 9.9 (14.5) 26.47 6.8441 18 50 
         
 Negative ----------- 1034 44.5 (62.1) 27.79 7.6217 17 60 
  LAIV 545 23.5 (32.7) 28.96 6.6858 18 48 
  TIV 489 21.0 (29.4) 26.48 8.3597 17 60 
         
Female ----------- ----------- 658 28.3 (100.0) 27.39 7.1904 18 54 
 Positive ----------- 192 8.3 (29.2) 26.21 6.2939 18 54 
  LAIV 99 4.3 (15.0) 26.47 5.7095 19 49 
  TIV 93 4.0 (14.1) 25.94 6.8822 18 54 
 Negative ------------ 466 20.1 (70.8) 27.87 7.4816 18 53 
  LAIV 229 9.9 (34.8) 28.57 7.5319 18 50 
  TIV 237 10.2 (36.0) 27.20 7.3863 18 53 
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Table 3-3 demonstrates the array of viruses, as well as frequency and percentages which 
were present in the population for the ’08-’09 season.   
Table 3-3.  Viruses identified for the ‘08-‘09 study population by laboratory testing. 
Virus Isolated Freq. Percent 
No Virus Isolated 1,328 57.14 




Adenovirus-14 15 0.65 
Enterovirus 15 0.65 
Parainfluenza 37 1.59 
RSV 2 0.09 
Rhinovirus 14 0.60 
Influenza A 11 0.47 
Influenza A/H1 100 4.30 
Influenza A/H3 56 2.41 
Influenza A/H3 & 
Rhinovirus 
1 0.04 




Influenza A/H1N1 & 
Adenovirus 
1 0.04 
   
Total 2,324 100.00 
 
After excluding those positive for pH1N1, 1712 (Table 3-4) were evaluated as seasonal 
influenza only.  Of these, 1195 (69.8%) were males and 517 (30.2%) females.  904 (52.8%) 
received the TIV, while 808 (47.2%) received the LAIV.  There were a total of 212 (12.4%) 
subjects who had a positive result for one of the surveyed types of influenza other than pH1N1.  
Males represented 161 (75.9%) of those who tested positive; with 101 (62.7%) of these received 
the LAIV, and the other 60 (37.3%) receiving the TIV.  Only 51 (24.1%) of the positives were 
female, with 29 (56.9%) receiving LAIV and 22 (43.1%) TIV.  The remaining 1500 (87.6%) had 
a result of either no virus isolated, or a virus other than influenza.  Of those, 774 (51.6%) 
received the LAIV.  The other 726 (48.4%) received the TIV.    
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‘08-‘09 Seasonal Influenza Only* 
Table 3-4. Snapshot of ’08-’09 Seasonal Influenza only study population   *Negatives do not 





# of obs Percent Mean 
Age 
s Min Age Max Age 
-------- ----------- ----------- 1712 100.0 27.89 7.5608 17 60 
 Positive ----------- 212 12.4 28.42 7.4470 18 54 
 Negative ----------- 1500 87.6 27.81 7.5761 17 60 
         
 ----------- LAIV 904 52.8 28.90 6.8491 18 50 
 ----------- TIV 808 47.2 26.76 8.1425 17 60 
         
Male ----------- ----------- 1195 69.8 (100.0) 27.90 7.5690 17 60 
 Positive ----------- 161 9.4 (13.5) 28.63 7.2014 18 49 
  LAIV 101 5.9 (8.5) 29.67 6.2082 18 46 
  TIV 60 3.5 (5.0) 26.87 8.3837 18 49 
         
 Negative ----------- 1034 60.4 (86.5) 27.79 7.6217 17 60 
  LAIV 545 31.8 (45.6) 28.96 6.6858 18 48 
  TIV 489 28.6 (40.9) 26.48 8.3597 17 60 
         
Female ----------- ----------- 517 30.2 (100.0) 27.86 7.5490 18 54 
 Positive ----------- 51 3.0 (9.9) 27.78 8.2178 18 54 
  LAIV 29 1.7 (2.4) 27.59 6.3162 21 44 
  TIV 22 1.3 (1.8) 28.05 10.367 18 54 
 Negative ------------ 466 27.2 (90.1) 27.87 7.4816 18 53 
  LAIV 229 13.4 (19.2) 28.57 7.5319 18 50 
  TIV 237 13.8 (19.8) 27.20 7.3863 18 53 
 
Table 3-5 demonstrates the array of viruses, as well as frequency and percentages which 
were present in the seasonal only population for the ’08-’09 season.   
Table 3-5. Viruses identified for the ‘08-‘09 study seasonal influenza population by laboratory 
testing 
 
Virus Isolated Freq. Percent 
No Virus Isolated 1,328 77.57 




Adenovirus-14 15 0.88 
Enterovirus 15 0.88 
Parainfluenza 37 2.16 
RSV 2 0.12 
Rhinovirus 14 0.82 
Influenza A 11 0.64 
Influenza A/H1 100 5.84 
Influenza A/H3 56 3.27 
Influenza A/H3 & 
Rhinovirus 
1 0.06 
Influenza B 44 2.57 
Total 1,712 100.00 
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When looking at both the entire population (Table 3-6), as well as the seasonal influenza 
only (Table 3-7) analyses for 08-09, males were 48% and 42% more likely to have a positive 
result for influenza (OR 1.483, 95% CI 1.214-1.813 & OR 1.422, 95% CI 1.010-2.027) 
respectively as compared to females.  This stands in direct contrast to the 10-11 results (Table 1-
2).   
Table 3-6. Sex vs. Influenza analysis, all subjects for ’08-’09 
 +Influenza - Influenza Total 
Males 632 1034 1666 
Females 192 466 658 
Total 824 1500 2324 
Odds Ratio 1.483  
95% CI 1.214-1.813  
p-value 0.0001  
Chi-Square Statistic 15.80  
 
Table 3-7. Sex vs. Influenza analysis, Seasonal Influenza only for ’09-’10 
 +Influenza - Influenza Total 
Males 161 1034 1195 
Females 51 466 517 
Total 212 1500 1712 
Odds Ratio 1.422  
95% CI 1.010-2.027  
p-value 0.0374  
Chi-Square Statistic 4.33  
 
However, in line with the ‘10-‘11 results, both of the ‘08-‘09 analyses (Tables 3-8 & 3-9) 
again demonstrated a protective benefit of the TIV form of the vaccine when compared to the 
LAIV.  For all subjects the TIV form was 27% more effective, and 33% more so when only the 
seasonal were considered (OR 0.7266, 95% CI 0.6095-0.8663 & OR 0.6724, 95% CI 0.4945-
0.9111 respectively).  
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Table 3-8. Vaccine form vs. Influenza analysis, all subjects for ’08-‘09 
Vaccine Forms 
 
+Influenza - Influenza Total 
TIV 334 726 1060 
LAIV 490 774 1264 
Total 824 1500 2324 
Odds Ratio 0. 7266  
95% CI 0. 6095-0. 8663  
p-value 0.0003  
Chi-Square Statistic 13.27  
 
Table 3-9. Vaccine form vs. Influenza analysis, Seasonal Influenza only for ’08-‘09 
Vaccine Forms +Influenza - Influenza Total 
TIV 82 726 808 
LAIV 130 774 904 
Total 212 1500 1712 
Odds Ratio 0. 6724  
95% CI 0. 4945-0. 9111  
p-value 0.0080  
Chi-Square Statistic 7.04  
 
Males (Tables 3-10 & 3-11) received 33% better protection from the TIV when 
considering all influenzas, and 34% better when considering only seasonal, than did males 
receiving the LAIV form in both analyses (OR 0.6869, 95% CI 0.5584-0.8446 & OR 0.6620, 
95% CI 0.4620-0.9435 respectively). 
Table 3-10. Vaccine form vs. Influenza analysis, Males only for ’08-‘09 
Males Only +Influenza - Influenza Total 
TIV 241 489 730 
LAIV 391 545 936 
Total 632 1034 1666 
Odds Ratio 0.6869  
95% CI 0.5584-0.8446  
p-value 0.0003  
Chi-Square Statistic 13.37  
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Table 3-11. Vaccine form vs. Influenza analysis, Males only, Seasonal Influenza only for ’08-‘09 
Males Only +Influenza - Influenza Total 
TIV 60 489 549 
LAIV 101 545 646 
Total 161 1034 1195 
Odds Ratio 0. 6620  
95% CI 0. 4620-0.9435  
p-value 0.0176  
Chi-Square Statistic 5.64  
 
However, females only (Tables 3-12 & 3-13) failed to reach any statistical significance.  
Table 3-12. Vaccine form vs. Influenza analysis, Females only for ’08-‘09 
Females Only +Influenza - Influenza Total 
TIV 93 237 330 
LAIV 99 229 328 
Total 192 466 658 
Odds Ratio 0.9076  
95% CI 0.6391-1.288  
p-value 0.5724  
Chi-Square Statistic 0.32  
 
Table 3-13. Vaccine form vs. Influenza analysis, Females only, Seasonal Influenza only for ’08-
‘09 
 
Females Only +Influenza - Influenza Total 
TIV 22 237 259 
LAIV 29 229 258 
Total 51 466 517 
Odds Ratio 0. 7330  
95% CI 0. 3891-1.364  
Pearson’s 0.2951  
Chi-Square 1.10  
 
One other interesting note, when looking at LAIV only for all subjects (Table 3-14), 
being male increased the risk by 66% as compared to females. (OR 1.659, 95% CI 1.258-2.196).  
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This trend was also present when looking at seasonal influenzas only (Table 3-16); however it 
failed to reach statistical significance (OR 1.4633, p-value 0.0890). 
Table 3-14. Sex vs. Influenza analysis for LAIV only, ’08-’09 
 
LAIV Only +Influenza - Influenza Total 
Males 391 545 936 
Females 99 229 328 
Total 490 774 1264 
Odds Ratio 1.659  
95% CI 1.258-2.196  
p-value 0.0002  
Chi-Square Statistic 13.75  
 
Table 3-15. Sex vs. Influenza analysis for LAIV, Seasonal Influenza only, ’08-’09 
LAIV Only +Influenza - Influenza Total 
Males 101 545 646 
Females 29 229 258 
Total 130 774 904 
Odds Ratio 1.4633  
95% CI 0.9292-2.360  
p-value 0.0890  
Chi-Square Statistic 2.89  
 
The remaining analyses (Tables 3-16 & 3-17) failed to demonstrate a level of acceptable 
statistical significance. 
Table 3-16. Sex vs. Influenza analysis for TIV only, ’08-’09 
TIV Only +Influenza - Influenza Total 
Males 241 489 730 
Females 93 237 330 
Total 334 726 1060 
Odds Ratio 1.255  
95% CI 0.9363-1.690  
p-value 0.1169  
Chi-Square Statistic 2.46  
 
DIFFERENCES IN INFLUENZA VACCINATION IMMUNITY 31 
 
Table 3-17. Sex vs. Influenza analysis for TIV, Seasonal Influenza only, ’08-’09 
TIV Only +Influenza - Influenza Total 
Males 60 489 549 
Females 22 237 259 
Total 82 726 808 
Odds Ratio 1. 321  
95% CI 0.7767-2.319  
p-value 0.2848  
Chi-Square Statistic 1.14  
 
‘07-‘08: 
In the initial dataset, there were 1,662 records total; 431 were eliminated for missing data, 
including no confirmatory testing, no date of vaccination, no reported gender, and missing 
vaccine types.  Again as with previous seasons, age group and gender comparisons showed 
reasonable similarity (Table 4-1).    
Table 4-1. Comparison of USAF Active Duty personnel to the ‘07-‘08 study population 
USAF End Strength - September 2007 Study Group 
 
# % # % 







24.1 17-24 FEMALE 
MALE 84,930 77.2 161 75.9 
TOTAL 109,281 100 212 100 






      
25.9 FEMALE 
MALE 103,155 79.5 123 74.1 
TOTAL 129,717 100 166 100 








MALE 65,381 85.2 90 79.7 
TOTAL 76,771 100 113 100 








MALE 10,933 83.8 16 88.9 







MALE 264,399 80.4 390 76.6 
TOTAL 328,808 100 509 100 
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Table 4-2 demonstrates the array of viruses, as well as frequency and percentages which 
were present in the study population for the ’07-’08 season.   
Table 4-2. Viruses identified for the ‘07-‘08 study seasonal influenza population by laboratory 
testing 
 
Isolated Virus Freq. Percent 
No Virus Isolated 338 66.40 




Adenovirus-14 50 9.82 
Enterovirus 3 0.59 
Parainfluenza 5 0.98 
RSV 1 0.20 
Rhinovirus 9 1.77 
Influenza A 28 5.50 
Influenza A & 
Adenovirus 14 
1 0.20 
Influenza A/H1 38 7.47 
Influenza B 26 5.11 
   
Total 509 100.00 
 
Of the remaining 1,231, 509 (Table 4-3) should have acquired immunity based on 
appropriate vaccination dates.  The other 722 were eliminated either due to receiving their 
vaccine after they had been tested, or within the 14 day window.  This included 390 (76.6%) 
males and 119 (23.4%) females.  TIV was given to 233 (45.8%), while 276 (54.2%) received the 
LAIV.   
There were a total of 93 (18.3%) subjects who had a positive result for one of the 
surveyed types of influenza.  It should be noted here that the A/H1 circulating in that season was 
a pre-pandemic seasonal variety, and not considered the same as the pH1N1.  Males constituted 
70 (75.3%) of those who tested positive; with 46 (65.7%), receiving the LAIV, compared with 
24 (34.3%) who received the TIV.  Females were 23 (24.7%) of the positives; 16 (69.6%) of 
these received the LAIV, compared to 7 (30.4%) who received the TIV.  The remaining 416 
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(81.7%) had a result of either no virus isolated, or a virus other than influenza.  Of those, 214 
(51.4%) received the LAIV.  The other 202 (48.6%) received the TIV.    





# of obs Percent Mean Age s Min Age Max Age 
-------- ----------- ----------- 509 100.0 28.23 8.2082 17 58 
 Positive  ----------- 93 18.3 31.27 7.3487 18 47 
 Negative  ----------- 416 81.7 27.55 8.2443 17 58 
         
 ----------- LAIV 276 54.2 29.00 7.5976 18 47 
 ----------- TIV 233 45.8  27.32 8.8070 17 58 
         
Male ----------- ----------- 390 76.6 (100.0) 28.52 8.3468 18 58 
 Positive ----------- 70  13.8 (18.0) 32.30 7.4042 19 47 
  LAIV 46 9.0 (11.8) 30.39 7.1414 19 44 
  TIV 24 4.7 (6.2) 35.96 6.5904 21 47 
         
 Negative ----------- 320 76.9 (82.1) 27.69 8.3234 18 58 
  LAIV 173 34.0 (44.4) 29.36 7.8702 18 47 
  TIV 147 28.9 (37.7) 25.73 8.4410 18 58 
         
Female ----------- ----------- 119 23.3 (100.0) 27.27 7.6932 17 50 
 Positive ----------- 23  4.5 (19.3) 28.13 6.3411 18 42 
  LAIV 16 3.1 (13.4) 26.69 5.7471 18 40 
  TIV 7 1.4 (5.9) 31.43 6.8278 24 42 
 Negative ------------ 96 23.1 (80.7) 27.07 7.9990 17 50 
  LAIV 41 8.1 (34.4) 26.83 7.1411 18 45 
  TIV 55 10.8 (46.2) 27.25 8.6436 17 50 
 
During this season, as with ‘10-’11, and both analyses for ‘08-‘09; the TIV vaccine form 
demonstrated a greater degree of protection by 47% (Table 4-4) when compared to the LAIV 
(OR 0.5297, 95% CI 0.3189-0.8683).   
Table 4-4. Vaccine form vs. Influenza analysis, all subjects for ’07-‘08 
Vaccine Forms +Influenza - Influenza Total 
TIV 31 202 233 
LAIV 62 214 276 
Total 93 416 509 
Odds Ratio 0.5297  
95% CI 0.3189-0.8683  
p-value 0.0077  
Chi-Square Statistic 7.10  
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And interestingly, females only (Table 4-5) also demonstrated 67% better protection after 
receiving the TIV when compared to the LAIV form of the vaccine (OR 0.3261, 95% CI 0.1044-
0.9413).   
Table 4-5. Vaccine form vs. Influenza analysis, Females only for ’07-‘08 
Females Only +Influenza - Influenza Total 
TIV 7 55 62 
LAIV 16 41 57 
Total 23 96 119 
Odds Ratio 0. 3261  
95% CI 0. 1044-0.9413  
p-value 0.0206  
Chi-Square Statistic 5.36  
 
The remaining analyses (Tables 4-6 through 4-9) failed to demonstrate a level of 
acceptable statistical significance. 
Table 4-6. Sex vs. Influenza analysis for ’07-’08 
 +Influenza - Influenza Total 
Males 70 320 390 
Females 23 96 119 
Total 93 416 509 
Odds Ratio 0.9130  
95% CI 0.5294-1.618  
p-value 0.7333  
Chi-Square Statistic 0.12  
 
Table 4-7. Vaccine form vs. Influenza analysis, Males only for ’07-‘08 
Males Only +Influenza - Influenza Total 
TIV 24 147 171 
LAIV 46 173 219 
Total 70 320 390 
Odds Ratio 0.6140  
95% CI 0. 3415-1.085  
p-value 0.0751  
Chi-Square Statistic 3.17  
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Table 4-8. Sex vs. Influenza analysis for LAIV only, ’07-‘08 
LAIV Only +Influenza - Influenza Total 
Males 46 173 219 
Females 16 41 57 
Total 62 214 276 
Odds Ratio 0.6813  
95% CI 0. 3379-1.423  
p-value 0.2091  
Chi-Square Statistic 1.58  
 
Table 4-9. Sex vs. Influenza analysis for TIV only, ’07-‘08 
TIV Only +Influenza - Influenza Total 
Males 24 147 171 
Females 7 55 62 
Total 31 202 233 
Odds Ratio 1.282  
95% CI 0. 4990-3. 726  
p-value 0.5856  
Chi-Square Statistic 0.30  
 
Discussion 
The original hypothesis for this study was that from 2006-2011, Active Duty Air Force 
males were provided better protection by the influenza vaccination than were females.  However, 
it is apparent that there is insufficient evidence in these findings to reject the null hypothesis.  In 
other words, there appears to be no consistent evidence in the study populations that the 
influenza vaccine provided better protection for one sex compared to the other.  While there may 
have been some instances of one sex receiving apparently better protection, these findings were 
not consistent. 
Despite this lack of support for the primary hypothesis, an interesting secondary finding 
did emerge.  This being that with the exception of the ‘09-‘10 influenza season, the TIV form of 
the vaccine provided better protection than the LAIV form against influenza infection.  In three 
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of the four seasons studied, and four of the six analyses, this improved protection was consistent 
and met statistical significance.  This finding in fact is not novel, and though not well explained 
it was also seen in the 2010 study by Johns et al., as well as a soon to be published study by 
Eick-Cost, Tastad, Guerrero, et al. 
There are a few reasons why this phenomenon may not have been seen during the ‘09-‘10 
season.  These include the possibility that there may have been some unknown confounding 
factor in the sample population, an undiscovered bias in the analysis, or that the supplemental 
vaccines were more closely matched to circulating strains due to their having been produced 
relatively late in the season.  This would potentially allow less time for genetic shift or drift to 
affect the outcomes.  Another possibility may simply be the fact that in the study population at 
least, overall influenza rates for ‘09-‘10 (both seasonal and pH1N1) were much lower than the 
other seasons presented here (Figure 2). 
 
Figure 2. Rates of pH1N1 infection vs. seasonal influenza during the study period 
Another interesting finding was the lack of any positive results among subjects from the 
‘09-‘10 season who received the preservative-free version of the supplemental vaccine.  There 









10-'11 09-'10 08-'09 07-'08
seasonal influenzas
pH1N1
DIFFERENCES IN INFLUENZA VACCINATION IMMUNITY 37 
 
immunogenicity is not clearly supported in the literature, which primarily focuses on the 
preservative-free vaccine being at least as affective as its thimerosol-containing counterpart 
(Banzhoff, Schwenke, & Febbraro, 2000).  Due to the design of this study, it was not practical to 
tease this subset for further analysis.  However, this may present an area for future research. 
This study has numerous strengths and limitations.  One factor which may be considered 
both is that the typical immunization rate among U.S. military personnel is >90%.  At the writing 
of this paper, the ‘11-‘12 vaccination rate for the USAF stood at 97% (Armed Forces Health 
Surveillance Center, 2012).  This is a strength in that it provides a large, uniformly immunized 
study population from which to draw.  But conversely as Eick-Cost et al. (n.d.) pointed out, 
similar age ranges of the U.S. civilian population only have vaccination rates approaching 38%.  
Therefore, these inferences may not translate well between the two populations. 
The ability to use laboratory-confirmed data to establish both cases and controls provides 
a definite strength.  Another strength is using a population base which receives essentially all its 
health care from one source, and that source does a reasonable job of maintaining centralized 
documentation of that care.  By virtue of the USAF population being relatively young and 
healthy, another strength provided is the lack of comorbidities which could present confounding 
difficulties regarding the analysis. 
Certainly, the inability to use the 2006 data presents a weakness.  Other weaknesses 
include the potential for influenza to actually be under-reported in a relatively young, healthy 
population.  Particularly for the ‘09-‘10 season, at the height of the pandemic many Air Force 
installations were instructing those with ILI-like symptoms to simply stay at home if possible in 
order to avoid spreading the illness. 
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There are areas of this data which remain rife for future study.  One such focus would be 
to look more closely at length of time between vaccination and testing to see if immunogenicity 
is more directly related to time intervals.  Also, as all the testing locations are available through 
these databases, a comparison involving geographic location may shed some light on the 
question of vaccination response.  Both of these questions may be enhanced by looking at the 
possible genetic drift and/or shift of the influenza virus as it relates to the factors of time interval 
and geographic location. 
Influenza remains a serious threat to global health, and vaccination continues to be a key 
tool in our armamentarium used to combat that illness.  As such, further studies should be 
undertaken in order to assist us in producing more effective vaccines, and vaccination strategies. 
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Appendix C: Public Health Competencies Met 
Specific Competencies 
Domain #1: Analytic Assessment Skill 
Defines a problems 
Determines appropriate uses and limitations of both quantitative and qualitative data 
Selects and defines variables relevant to defined public health problems 
Identifies relevant and appropriate data and information sources 
Evaluates the integrity and comparability of data and identifies gaps in data sources 
Makes relevant inferences from quantitative and qualitative data 
Applies data collection processes, information technology applications, and computer systems 
storage/retrieval strategies 
Recognizes how the data illuminates ethical, political, scientific, economic, and overall public health issues 
Domain #2: Policy Development/Program Planning Skills 
Collects, summarizes, and interprets information relevant to an issue 
Articulates the health, fiscal, administrative, legal, social, and political implications of each policy option 
Utilizes current techniques in decision analysis and health planning 
Domain #3: Communication Skills 
Communicates effectively both in writing and orally, or in other ways 
Solicits input from individuals and organizations 
Effectively presents accurate demographic, statistical, programmatic, and scientific information for 
professional and lay audiences 
Attitudes 
Listens to others in an unbiased manner, respects points of view of others, and promotes the expression of 
diverse opinions and perspectives 
Domain #4: Cultural Competency Skills - N/A 
Domain #5: Community Dimensions of Practice Skills 
Establishes and maintains linkages with key stakeholders 
Identifies how public and private organizations operate within a community 
Identifies community assets and available resources 
Domain #6: Basic Public Health Sciences Skills 
Defines, assesses, and understands the health status of populations, determinants of health and illness, 
factors contributing to health promotion and disease prevention, and factors influencing the use of health 
services 
Understands the historical development, structure, and interaction of public health and health care 
systems 
Identifies and applies basic research methods used in public health 
Applies the basic public health sciences including behavioral and social sciences, biostatistics, 
epidemiology, environmental public health, and prevention of chronic and infectious diseases and injuries 
Identifies and retrieves current relevant scientific evidence 
Identifies the limitations of research and the importance of observations and interrelationships 
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Specific Competencies 
Domain #7: Financial Planning and Management Skills 
Manages information systems for collection, retrieval, and use of data for decision-making 
Domain #8: Leadership and Systems Thinking Skills 
Identifies internal and external issues that may impact delivery of essential public health services (i.e. 
strategic planning) 
 
